Lexicon Pharmaceuticals Net Income 2006-2021 | LXRX

Lexicon Pharmaceuticals net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Lexicon Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-59
2019 $130
2018 $-121
2017 $-123
2016 $-131
2015 $-5
2014 $-100
2013 $-104
2012 $-110
2011 $-116
2010 $-102
2009 $-83
2008 $-77
2007 $-59
2006 $-54
2005 $-36
Lexicon Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $-23
2021-06-30 $-18
2021-03-31 $-21
2020-12-31 $-5
2020-09-30 $83
2020-06-30 $-69
2020-03-31 $-67
2019-12-31 $-51
2019-09-30 $226
2019-06-30 $-23
2019-03-31 $-22
2018-12-31 $-17
2018-09-30 $-27
2018-06-30 $-35
2018-03-31 $-42
2017-12-31 $-22
2017-09-30 $-31
2017-06-30 $-35
2017-03-31 $-35
2016-12-31 $-22
2016-09-30 $-36
2016-06-30 $-38
2016-03-31 $-35
2015-12-31 $87
2015-09-30 $-35
2015-06-30 $-28
2015-03-31 $-28
2014-12-31 $-3
2014-09-30 $-40
2014-06-30 $-26
2014-03-31 $-31
2013-12-31 $-17
2013-09-30 $-32
2013-06-30 $-29
2013-03-31 $-26
2012-12-31 $-25
2012-09-30 $-30
2012-06-30 $-26
2012-03-31 $-30
2011-12-31 $-34
2011-09-30 $-26
2011-06-30 $-27
2011-03-31 $-30
2010-12-31 $-23
2010-09-30 $-28
2010-06-30 $-25
2010-03-31 $-26
2009-12-31 $-22
2009-09-30 $-19
2009-06-30 $-20
2009-03-31 $-22
2008-12-31 $-15
2008-09-30 $-23
2008-06-30 $-20
2008-03-31 $-18
2007-12-31 $-12
2007-09-30 $-14
2007-06-30 $-14
2007-03-31 $-19
2006-12-31 $-14
2006-09-30 $-13
2006-06-30 $-17
2006-03-31 $-11
2005-12-31 $6
2005-09-30 $-14
2005-06-30 $-15
2005-03-31 $-13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.514B $0.024B
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomictechnologies to accelerate large-scale analysis of mammalian gene function for drug discovery.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69